S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Why Does Proctor & Gamble Need a Dental Laser?

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

From BioHealth Investor

by H.S. Ayoub
BioHealth Investor.com

BioLase Technology (BLTI) announced early Thursday that the company had signed a definitive agreement with Proctor & Gamble (PG).

Under the terms of the agreement PG will have access to BioLase’s dental laser intellectual property for the development of certain consumer products. BioLase will receive loyalties and quarterly payments of $250,000.

A binding agreement was agreed upon back in June, after which BioLase collected an upfront payment of $3 million.

So what exactly could PG use this technology for? While financial details of the agreement will be more apparent in a future filing with the SEC, any products developed by PG using the technology might not be announced for some time. Could consumers be buying an at-home dental laser whitening system in the future?

As for BioLase’s end of the deal it is difficult to critique without a hint at how much the royalties could sum up to. Looking at the upfront payment of $3 million, and the quarterly payments of $250,000 alone one would rebuff the deal. The company posted losses of $17 million in 2005 and $23 million in 2004.

http://www.biohealthinvestor.com/

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

5 Red-Hot Stocks Trading Under $10 With Massive Upside Potential
Lee Jackson |

5 Red-Hot Stocks Trading Under $10 With Massive Upside Potential

These are five stocks for aggressive investors that look to get share count leverage on companies that have sizable upside…
Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?
Chris Lange |

Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?

Eleven Biotherapeutics is continuing to rise this week after the company announced the effectiveness of the exclusive licensing deal with…
New Research Partnership With Horizon Therapeutics Could Be the Next Revenue Catalyst for Xeris
247patrick |

New Research Partnership With Horizon Therapeutics Could Be the Next Revenue Catalyst for Xeris

Xeris gets cash injection from Horizon Therapeutics.
Big Acquisition Doubles Exxon Mobil’s Permian Basin Oil Assets
Jon C. Ogg |

Big Acquisition Doubles Exxon Mobil’s Permian Basin Oil Assets

If there is one area of the United States that continues to enchant and enthrall energy investors and operators alike,…
Is Editas Facing a New Reality in CRISPR Land?
Jon C. Ogg |

Is Editas Facing a New Reality in CRISPR Land?

Big opportunities in emerging health care companies often come with very bumpy rides. There is also the risk, of course,…
Douglas A. McIntyre |

Biotech Indices Mixed as AMEX Gains, Nasdaq Slips

From BioHealth Investor by H.S. AyoubBioHealth Investor.com The major biotech indices were mixed on Monday. The AMEX Biotechnology Index (^BTK)…
Douglas A. McIntyre |

Palomar Dumped by J&J (PMTI, JNJ)

Palomar Medical Technologies Inc. (NASDAQ: PMTI) is getting hit very hard.  The company issued a press release saying “Palomar to…
Is Spectrum Pharma Getting Enough for Its Hematology/Oncology Portfolio?
Chris Lange |

Is Spectrum Pharma Getting Enough for Its Hematology/Oncology Portfolio?

Spectrum Pharmaceuticals on Thursday after the firm announced that it would be selling its portfolio of seven FDA-approved hematology/oncology products…
Douglas A. McIntyre |

Durect Having Great Week with Painkiller News

From BioHealth Investor Durect Corporation (DRRX) is having a great week so far. The company inked a deal with Danish…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618